Lab21’s blood bank business sold to Trinity Biotech

Lab 21 has sold its blood bank screening business to Trinity Biotech for $7.5 million. Backed by high-profile healthcare entrepreneur and investor Professor Sir Christopher Evans OBE PhD’s Excalibur Group, Lab 21 is a medicine diagnostic specialist supporting healthcare providers, the pharmaceutical and biotechnology industries with technically advanced products and services. Livingstone advised on the transaction.

North AmericaUSBriefs